Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Etf Ticker Symbol | Market | Type |
|---|---|---|---|
| iShares Morningstar Multi Asset Income ETF | IYLD | AMEX | Exchange Traded Fund |
| Price Change | Change Percent | Etf Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 19.0665 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 19.0665 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 17.83 - 22.46 |
| Last Trade Time | Type | Quantity | Etf Price | Currency |
|---|---|---|---|---|
| - | 0 | 19.0665 | USD |
iShares Morningstar Multi Asset Income ETF Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 143.00M | 7.50M | 7.50M | - | - | - | 5.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | 5.67% | 03/02/23 | - | - |
News iShares Morningstar Mult...
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
IYLD Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 19.005 | 19.10 | 18.73 | 18.90 | 16,232 | 0.0615 | 0.32% |
| 1 Month | 19.21 | 19.545 | 18.69 | 19.03 | 15,898 | -0.1435 | -0.75% |
| 3 Months | 19.12 | 20.36 | 18.69 | 19.77 | 42,299 | -0.0535 | -0.28% |
| 6 Months | 18.38 | 20.36 | 17.83 | 19.22 | 60,049 | 0.6865 | 3.74% |
| 1 Year | 22.2801 | 22.46 | 17.83 | 19.70 | 55,469 | -3.21 | -14.42% |
| 3 Years | 20.16 | 25.02 | 17.83 | 21.44 | 47,842 | -1.09 | -5.42% |
| 5 Years | 24.88 | 26.08 | 17.59 | 22.82 | 56,076 | -5.81 | -23.37% |
| The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. |